Close

GSK to acquire 25% stake in Aspen Japan

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Under-Eye Wrinkle Treatment: How to Reduce Puffiness and Fine Lines

As we age, the skin around our eyes begins...

Receptor Grade IGF-1 LR3: Expansive Research Potential

Receptor Grade IGF-1 LR3, an engineered analog of Insulin-like...

API China 2025 kicks off with Industry Buzz on Day One

At the China Import and Export Fair Complex in...

FDA Plans to Deploy AI Tools for Scientific Reviews

The US Food and Drug Administration has announced plans...

British drug maker GlaxoSmithKline (GSK) has signed an agreement with Aspen Global (AGI) to acquire interest in its newly established subsidiary Aspen Japan.

As part of the deal, GSK will acquire a 25% interest in Aspen Japan, while the remaining stake will be owned by Aspen.

The agreement will allow Aspen Japan to carry out its commercial operations in the country through a strategic alliance with GSK.

AGI will transfer the marketing authorisations and grant perpetual distribution rights to Aspen Japan for all products.

In accordance with the collaboration, AGI will transfer the marketing authorisations and grant perpetual distribution rights to Aspen Japan for all products, which are presently being marketed and supplied on behalf of Aspen in Japan.

GSK will also transfer the marketing authorisations and grant distribution rights to Aspen Japan for certain mature products in its portfolio.

In addition, GSK will provide a pipeline of authorised generics for its multiple products to Aspen Japan, while AGI will offer the rights of all future products, which it acquires or licenses in Japan.

AGI will take care of the management of Aspen Japan, as well as commercialisation of all the products in its portfolio.

Completion of the deal is subject to multiple conditions, including Aspen Japan obtaining accreditation as a marketing authorisation holder from the relevant Japanese regulatory authority.

Latest stories

Related stories

Under-Eye Wrinkle Treatment: How to Reduce Puffiness and Fine Lines

As we age, the skin around our eyes begins...

Receptor Grade IGF-1 LR3: Expansive Research Potential

Receptor Grade IGF-1 LR3, an engineered analog of Insulin-like...

API China 2025 kicks off with Industry Buzz on Day One

At the China Import and Export Fair Complex in...

FDA Plans to Deploy AI Tools for Scientific Reviews

The US Food and Drug Administration has announced plans...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back